✦ LIBER ✦

48 weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection

✍ Scribed by C.-K. HUI; L. S. W. LAI; P. LAM; H.-Y. ZHANG; T.-T. FUNG; S.-T. LAI; W.-M. WONG; C.-M. LO; S.-T. FAN; N. LEUNG; G. K. K. LAU; THE HONG KONG LIVER FIBROSIS STUDY GROUP

Book ID: 108604528
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 111 KB
Volume: 23
Category: Article
ISSN: 0269-2813
DOI: 10.1111/j.1365-2036.2006.02887.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of chronic hepatitis E in live

Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b

✍ Elizabeth B. Haagsma; Annelies Riezebos-Brilman; Arie P. van den Berg; Robert J. 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 1 views

Hepatitis E virus (HEV) infections are known to run a self-limiting course. Recently, chronic hepatitis E has been described in immunosuppressed patients after solid-organ transplantation. Besides the general recommendation to lower the immunosuppressive medication in these patients, there is curren

α-2-HS-glycoprotein is a potential marke

α-2-HS-glycoprotein is a potential marker predicting hepatitis B e antigen seroconversion in patients with chronic hepatitis B during treatment with pegylated interferon alfa-2b

✍ Hui Ma; JiangHua Wang; Fang Guo; Lai Wei 📂 Article 📅 2011 🏛 Science in China Press (SCP) 🌐 English ⚖ 719 KB

Mutations in the interferon sensitivity

Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection

✍ Mina Nakagawa; Naoya Sakamoto; Mayumi Ueyama; Kaoru Mogushi; Satoshi Nagaie; Yas 📂 Article 📅 2010 🏛 Springer Japan 🌐 English ⚖ 266 KB

Adverse skin reactions due to pegylated

Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus

✍ Yuki HASHIMOTO; Hiromi KANTO; Masatoshi ITOH 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 1023 KB

Pretreatment prediction of anemia progre

Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis

✍ Naoki Hiramatsu; Masayuki Kurosaki; Naoya Sakamoto; Manabu Iwasaki; Minoru Sakam 📂 Article 📅 2011 🏛 Springer Japan 🌐 English ⚖ 264 KB

The safety of pegylated interferon alpha

The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation

✍ M. van Zonneveld; H. J. Flink; E. Verhey; H. Senturk; S. Zeuzem; U. S. Akarca; Y 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB